Epeius Biotechnologies Rexin-G News


News items related to Epeius Biotechnologies Rexin-G as issued by the Send2Press Newswire service on behalf of the noted news source.


Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma

SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy.

Targeted Gene Delivery Signals Cancer Vaccination in Vivo

SAN MARINO, Calif., May 27 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G followed by Reximmune-C-for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J Clin Oncol 26:3077, 2008). Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles bearing a cytocidal cyclin G1 gene and a granulocyte-macrophage colony stimulating factor (GM-CSF) gene, respectively.